Omada Health, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ryan MacDonald from Needham reiterated a Buy rating on the stock and has a $28.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan MacDonald has given his Buy rating due to a combination of factors that point to both solid execution and attractive upside potential. He highlights Omada Health’s stronger-than-expected finish to 2025, with revenue and membership figures coming in ahead of market expectations, which reinforces confidence in the company’s growth trajectory into 2026. In his view, the evolving GLP-1 landscape—with falling drug prices and rising benefit-design complexity—should prompt more employers to seek either complementary GLP-1 solutions or non-GLP-1 alternatives, a trend that plays directly into Omada’s strengths.
MacDonald also underscores that Omada is well positioned to win new customers in both of these benefit-design scenarios, while its emerging prescribing offering should deepen engagement within its existing client base and improve profitability. On top of these operational and strategic advantages, he notes that the stock is currently trading at a modest multiple of his 2026 revenue estimate, suggesting meaningful valuation upside relative to its growth prospects. Collectively, these dynamics support his decision to reiterate a Buy rating and maintain a favorable outlook on the shares.
In another report released on January 16, Goldman Sachs also maintained a Buy rating on the stock with a $26.00 price target.